UBS Group’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $166K | Sell |
24,759
-26,280
| -51% | -$177K | ﹤0.01% | 5591 |
|
|
2025
Q1 | $461K | Sell |
51,039
-2,052
| -4% | -$18.6K | ﹤0.01% | 4732 |
|
|
2024
Q4 | $918K | Buy |
53,091
+28,100
| +112% | +$486K | ﹤0.01% | 4275 |
|
|
2024
Q3 | $399K | Buy |
24,991
+3,176
| +15% | +$50.8K | ﹤0.01% | 4243 |
|
|
2024
Q2 | $311K | Sell |
21,815
-1,654
| -7% | -$23.6K | ﹤0.01% | 4270 |
|
|
2024
Q1 | $333K | Buy |
23,469
+993
| +4% | +$14.1K | ﹤0.01% | 4375 |
|
|
2023
Q4 | $339K | Buy |
22,476
+9,165
| +69% | +$138K | ﹤0.01% | 4258 |
|
|
2023
Q3 | $210K | Sell |
13,311
-377
| -3% | -$5.96K | ﹤0.01% | 4238 |
|
|
2023
Q2 | $207K | Buy |
13,688
+12,231
| +839% | +$185K | ﹤0.01% | 4423 |
|
|
2023
Q1 | $21.1K | Buy |
1,457
+200
| +16% | +$2.9K | ﹤0.01% | 5945 |
|
|
2022
Q4 | $17K | Buy |
+1,257
| New | +$17K | ﹤0.01% | 6681 |
|
|
2022
Q3 | – | Sell |
-597
| Closed | -$8K | – | 9695 |
|
|
2022
Q2 | $8K | Sell |
597
-850
| -59% | -$11.4K | ﹤0.01% | 7312 |
|
|
2022
Q1 | $13K | Sell |
1,447
-1,367
| -49% | -$12.3K | ﹤0.01% | 7030 |
|
|
2021
Q4 | $48K | Buy |
+2,814
| New | +$48K | ﹤0.01% | 5845 |
|